Navigation Links
Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
Date:8/6/2009

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and treasurer. Mr. Driscoll will report to Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer.

Previously Mr. Driscoll served as Chief Financial Officer, and President and Chief Executive Officer of Genelabs Technologies, Inc. Prior to his position at Genelabs, Mr. Driscoll served in a variety of financial and senior management positions at Astraris, Inc., OXiGENE, Inc. and Collagenesis Corp. He also spent more than twenty years with Instrumentation Laboratory as vice president of finance for the Americas.

Dr. Singhvi stated: "We are pleased to welcome Fred Driscoll to Novavax as our new chief financial officer. Fred is joining Novavax at a time of significant growth and his contribution at such a critical juncture will be welcome by everyone on our Executive Team. We are looking forward to tapping into his many years of biotechnology industry experience as we expand our vaccine development programs, manufacturing operations and international collaborations."

Mr. Michael A. McManus, Jr., Novavax's Audit Committee Chairman, commented: "Mr. Driscoll is a seasoned and talented executive with valuable experience in financial management, corporate strategy and fundraising, and investor relations. Fred has had considerable experience as a public company CFO and has raised significant funds in the capital markets. In addition, he enjoys a strong reputation in the investment community. We welcome him to our Executive team."

Mr. Driscoll received his bachelor's degree in accounting from Bentley College.

About Novavax

Novavax, Inc. is a clinical-stage biotec
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
2. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
3. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
4. Novavax Announces Repayment of $5 Million of Convertible Debt
5. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
6. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
7. Novavax Appoints Stanley Erck to Board of Directors
8. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
9. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
10. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
11. Novavax Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , More sensitive than ... Linear quantitation of mRNA targets , over a 106-fold range ... as 500 fg total RNA 1/20th of a single cell! , Fast, ... 15 min , , ...
... Fluorescence activated cell sorting (FACS) is a , ... individual cells using fluorescent probes that bind specifically to ... commonly used to collect , cells of a given ... , Figure 1.Linear Amplification from 1-1000 Cells. , ...
... Remove >90% of mammalian RNA from , ... Simple procedure takes less than 2 hours , ... with , MICROB Express Bacterial mRNA Purification Kit ... bacterial RNA isolated from host cells , ...
Cached Biology Technology:HIGH SENSITIVITY qRT-PCR 2HIGH SENSITIVITY qRT-PCR 3HIGH SENSITIVITY qRT-PCR 4HIGH SENSITIVITY qRT-PCR 5Cells-to-cDNA II Using FACS Sorted Cells 2Bacterial RNA Isolation From Infected Eukaryotic Hosts 2Bacterial RNA Isolation From Infected Eukaryotic Hosts 3Bacterial RNA Isolation From Infected Eukaryotic Hosts 4Bacterial RNA Isolation From Infected Eukaryotic Hosts 5Bacterial RNA Isolation From Infected Eukaryotic Hosts 6
(Date:4/17/2014)... ideas about domestication derive from Charles Darwin, whose ... animal-breeding practices during the 19th century, a period ... , It is from Darwin that we inherit ... animals from wild species and total human control ... management in this industrial setting has been applied ...
(Date:4/16/2014)... State University researchers have identified a new syndrome called ... and muscle mass with obesity. , "It used to ... better your bones would be because the bones were ... Professor of Nutrition at Florida State. "But, that,s only ...
(Date:4/16/2014)... Nicolas Doucet of the Centre INRSInstitut Armand-Frappier has just received ... in the amount of nearly US$600,000. The 5-year grant is ... called RNases and to explore their biomedical potential in the ... , "Receiving a grant at this level is ...
Breaking Biology News(10 mins):The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers: Obesity can amplify bone and muscle loss 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2
... U.S. west coast is among the richest ecosystems in the ... a great diversity of marine life. Like coastal regions in ... new study led by scientists at the University of California, ... impacts are highest on marine predators such as whales, seals, ...
... better electronics developed during the last decade, as ... energy storage, and clean water. However, exposure to ... and the environment. As a resource for ... Center for Sustainable Nanotechnology (VTSuN) has joined the ...
... University studying the cause of a rare childhood disease ... new findings may provide clues to understanding more common ... tools to treat them. In today,s online edition ... Hart and Jiali Li in the Department of Cell ...
Cached Biology News:Study maps human impacts on top ocean predators along US west coast 2Study maps human impacts on top ocean predators along US west coast 3Nanomaterials database improved to help consumers, scientists track products 2Nanomaterials database improved to help consumers, scientists track products 3Nanomaterials database improved to help consumers, scientists track products 4Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 2Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 3
...
... inhibition of RNase A-type ribonucleases Product Description: ... nonhuman origin that binds noncovalently and inactivates ... B, and C). It does not interfere ... or CL3. QIAGEN RNase Inhibitor inhibits greater ...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Biology Products: